Xenon Pharmaceuticals (XENE) Net Cash Flow (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Net Cash Flow data on file, last reported at $346.8 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $346.8 million, up 1434.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $428.8 million (up 625.21% YoY), and the FY2025 annual result was $56.0 million, up 1414.7% from the prior year.
• Net Cash Flow improved to $346.8 million in Q1 2026 per XENE's latest filing, from $94.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $346.8 million in Q1 2026 and troughed at -$263.8 million in Q3 2022.
• A 5-year average of $20.2 million and a median of $5.8 million in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 5427.59% in 2022 and fell as far as 5053.06% in 2022.
• A 5-year view of Net Cash Flow shows it stood at -$47.1 million in 2022, then soared by 203.74% to $48.8 million in 2023, then gained by 15.21% to $56.2 million in 2024, then jumped by 68.46% to $94.8 million in 2025, then surged by 266.04% to $346.8 million in 2026.
• Business Quant data shows XENE's Net Cash Flow at $346.8 million in Q1 2026, $94.8 million in Q4 2025, and -$30.9 million in Q3 2025.